Welcome to our dedicated page for Axe Compute SEC filings (Ticker: AGPU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Axe Compute Inc. (NASDAQ: AGPU) SEC filings page provides access to the company’s regulatory disclosures, including current and historical documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information about Axe Compute’s transition from Predictive Oncology Inc. to its present focus on high-performance AI infrastructure and AI-driven solutions.
Among the key documents are Form 8-K filings that report material events. For example, an 8-K dated in connection with the company’s name change notes that Axe Compute Inc. (formerly Predictive Oncology Inc.) began trading on Nasdaq under the ticker symbol AGPU on December 12, 2025. The same filing also describes amendments to an executive employment agreement and references the company’s 2024 Equity Incentive Plan.
Through this page, users can review annual reports (Form 10-K), quarterly reports (Form 10-Q), and other current reports that may discuss Axe Compute’s AI infrastructure strategy, its use of the Aethir network to secure GPU capacity, and its plans to operate as an active infrastructure operator. Filings can also include information about equity compensation, governance matters, and other corporate actions.
Stock Titan enhances these SEC filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the main themes and disclosures. Real-time updates from the EDGAR system ensure that new AGPU filings, including potential Form 4 insider transaction reports and proxy materials, are available as they are posted, with AI-generated insights to make the information more accessible.
Axe Compute Inc. reported several leadership changes. On January 15, 2026, directors Shawn Matthews and Veena Rao resigned from the board, with Ms. Rao’s resignation effective January 30, 2026. The company states that neither director resigned because of any disagreement over operations, policies, or practices.
On January 19, 2026, Thomas McLaughlin resigned as Chief Investment Officer, and the company likewise notes no disagreement related to its operations, policies, or practices. The filing does not describe replacements or broader strategic changes linked to these departures.
Axe Compute Inc., formerly Predictive Oncology Inc., amended the employment agreement of its CEO, Raymond F. Vennare. Effective retroactively to November 1, 2025, his annual base salary increases from $525,000 to $575,000. He is eligible for an annual target bonus on March 31, 2026, or an earlier date set by the compensation committee, in an amount equal to 50% of his then current base salary. If his employment is terminated without Cause or by him for Good Reason on or before March 31, 2026, his 2025 bonus will be 50% of his annual bonus as of the time of termination and must be paid in full no later than March 15, 2026.
Subject to the company’s 2024 Equity Incentive Plan and compensation committee approval, Mr. Vennare will be eligible to receive 20,000 restricted stock units that vest in full on January 1, 2026, if he remains continuously employed through that date. The company also disclosed that it changed its name to Axe Compute Inc. and that its common stock began trading on Nasdaq under the ticker symbol AGPU on December 12, 2025.
FAQ
What is the current stock price of Axe Compute (AGPU)?
What is the market cap of Axe Compute (AGPU)?
